Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer.
Mimura K, Ogata T, Yoshimoto Y, Yoshida D, Nakajima S, Sato H, Machida N, Yamada T, Watanabe Y, Tamaki T, Fujikawa H, Inokuchi Y, Hayase S, Hanayama H, Saze Z, Katoh H, Takahashi F, Oshima T, Suzuki Y, Kono K. Mimura K, et al. Among authors: machida n. Commun Med (Lond). 2023 Aug 15;3(1):111. doi: 10.1038/s43856-023-00343-4. Commun Med (Lond). 2023. PMID: 37582945 Free PMC article.
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Kawazoe A, Yamaguchi K, Yasui H, Negoro Y, Azuma M, Amagai K, Hara H, Baba H, Tsuda M, Hosaka H, Kawakami H, Oshima T, Omuro Y, Machida N, Esaki T, Yoshida K, Nishina T, Komatsu Y, Han SR, Shiratori S, Shitara K. Kawazoe A, et al. Among authors: machida n. Eur J Cancer. 2020 Apr;129:97-106. doi: 10.1016/j.ejca.2020.02.002. Epub 2020 Mar 4. Eur J Cancer. 2020. PMID: 32145474 Free article. Clinical Trial.
Effect of Prognostic Nutrition Index in Gastric or Gastro-oesophageal Junction Cancer Patients Undergoing Nivolumab Monotherapy.
Watanabe H, Yamada T, Komori K, Hara K, Kano K, Takahashi K, Kumazu Y, Fujikawa H, Numata M, Aoyama T, Tamagawa H, Inokuchi Y, Machida N, Shiozawa M, Yukawa N, Morinaga S, Rino Y, Masuda M, Ogata T, Oshima T. Watanabe H, et al. Among authors: machida n. In Vivo. 2021 Jan-Feb;35(1):563-569. doi: 10.21873/invivo.12292. In Vivo. 2021. PMID: 33402510 Free PMC article.
Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy.
Watanabe H, Fujikawa H, Komori K, Kano K, Takahashi K, Yamada T, Inokuchi Y, Machida N, Yokose T, Rino Y, Masuda M, Ogata T, Oshima T. Watanabe H, et al. Among authors: machida n. Case Rep Gastroenterol. 2021 Jun 23;15(2):562-567. doi: 10.1159/000514396. eCollection 2021 May-Aug. Case Rep Gastroenterol. 2021. PMID: 34616257 Free PMC article.
Feasibility of gastric endoscopic submucosal dissection in elderly patients aged ≥ 80 years.
Inokuchi Y, Ishida A, Hayashi K, Kaneta Y, Watanabe H, Kano K, Furuta M, Takahashi K, Fujikawa H, Yamada T, Yamamoto K, Machida N, Ogata T, Oshima T, Maeda S. Inokuchi Y, et al. Among authors: machida n. World J Gastrointest Endosc. 2022 Jan 16;14(1):49-62. doi: 10.4253/wjge.v14.i1.49. World J Gastrointest Endosc. 2022. PMID: 35116099 Free PMC article.
Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab.
Suematsu H, Kano K, Yamada T, Hashimoto I, Watanabe H, Takahashi K, Watanabe M, Hayashi K, Kaneta Y, Furuta M, Inokuchi Y, Machida N, Aoyama T, Tamagawa H, Yukawa N, Rino Y, Masuda M, Ogata T, Oshima T. Suematsu H, et al. Among authors: machida n. Anticancer Res. 2022 Mar;42(3):1535-1540. doi: 10.21873/anticanres.15626. Anticancer Res. 2022. PMID: 35220249
271 results